Analysts at Goldman Sachs Group started coverage on shares of Almirall (OTCMKTS:LBTSF) in a research report issued to clients and investors on Wednesday, Briefing.com Automated Import reports. The brokerage set a “buy” rating on the stock.
Several other brokerages have also recently issued reports on LBTSF. Jefferies Financial Group raised Almirall from a “hold” rating to a “buy” rating in a research note on Thursday, May 2nd. BNP Paribas raised Almirall from an “underperform” rating to a “neutral” rating in a research note on Friday, January 11th.
OTCMKTS:LBTSF remained flat at $$17.03 during midday trading on Wednesday. Almirall has a 12 month low of $13.15 and a 12 month high of $20.91.
Almirall, SA, a pharmaceutical company, engages in the research, development, manufacture, and sale of medicines worldwide. The company offers its products for dermatological diseases comprising actinic keratosis, atopic dermatitis, acne, rosacea, and psoriasis; and central nervous system, cardiovascular, and gastrointestinal diseases.
Read More: What is a Tariff?
Receive News & Ratings for Almirall Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Almirall and related companies with MarketBeat.com's FREE daily email newsletter.